Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 7/20 | 0.56 |
| ▸ | DRD4 | P21917 | 7/20 | 0.56 |
| ▸ | DRD3 | P35462 | 7/20 | 0.56 |
| ▸ | ACHE | P22303 | 6/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | BACE1 | P56817 | 4/20 | 0.46 |
| ▸ | BCHE | P06276 | 3/20 | 0.46 |
| ▸ | CCR3 | P51677 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13490557 | 0.86 | DRD2 (0.59) | DRD2DRD4DRD3ACHEMEN1 | |
| SCHEMBL13490458 | 0.82 | DRD2 (0.48) | DRD2DRD4DRD3ACHEPOLB | |
| SCHEMBL13490648 | 0.80 | DRD2 (0.60) | DRD2DRD4DRD3ACHEMEN1 | |
| SCHEMBL171521 | 0.77 | DRD2 (0.53) | DRD2DRD4DRD3ACHEMEN1 | |
| SCHEMBL169363 | 0.77 | DRD2 (0.60) | DRD2DRD4DRD3ACHEMEN1 | |
| SCHEMBL22642807 | 0.75 | DRD2 (0.58) | DRD2DRD4DRD3ACHEMEN1 | |
| SCHEMBL13490463 | 0.74 | DRD2 (0.51) | DRD2DRD4DRD3ACHEMEN1 | |
| SCHEMBL13490449 | 0.74 | DRD2 (0.59) | DRD2DRD4DRD3ACHEBCHE | |
| SCHEMBL13450177 | 0.73 | MEN1 (0.67) | DRD2DRD4DRD3ACHEMEN1 | |
| SCHEMBL13490647 | 0.73 | DRD2 (0.51) | DRD2DRD4DRD3ACHEBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029947-A1 | Pyridyltetrahydropyridines and Pyridylpiperidines, and Method of Manufacturing Them | FUJIFILM FINECHEMICALS CO., LTD | 2010-02-04 | — | — | US | disclosed |
| US-7632950-B2 | Pyridyltetrahydropyridines and pyridylpiperidines and method of manufacturing them | FUJIFILM FINECHEMICALS CO., LTD (JP) | 2009-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029947-A1 | Pyridyltetrahydropyridines and Pyridylpiperidines, and Method of Manufacturing Them | QDPR, HRH4, HRH2 | DRD2 130/4885DRD4 112/4885DRD3 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.